218 related articles for article (PubMed ID: 35118004)
1. Rifaximin Modulates the Gut Microbiota to Prevent Hepatic Encephalopathy in Liver Cirrhosis Without Impacting the Resistome.
Yu X; Jin Y; Zhou W; Xiao T; Wu Z; Su J; Gao H; Shen P; Zheng B; Luo Q; Li L; Xiao Y
Front Cell Infect Microbiol; 2021; 11():761192. PubMed ID: 35118004
[TBL] [Abstract][Full Text] [Related]
2. Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis.
Bajaj JS
Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():11-26. PubMed ID: 26618922
[TBL] [Abstract][Full Text] [Related]
3. Rifaximin-α reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial.
Patel VC; Lee S; McPhail MJW; Da Silva K; Guilly S; Zamalloa A; Witherden E; Støy S; Manakkat Vijay GK; Pons N; Galleron N; Huang X; Gencer S; Coen M; Tranah TH; Wendon JA; Bruce KD; Le Chatelier E; Ehrlich SD; Edwards LA; Shoaie S; Shawcross DL
J Hepatol; 2022 Feb; 76(2):332-342. PubMed ID: 34571050
[TBL] [Abstract][Full Text] [Related]
4. Sex is associated with differences in gut microbial composition and function in hepatic encephalopathy.
Saboo K; Shamsaddini A; Iyer MV; Hu C; Fagan A; Gavis EA; White MB; Fuchs M; Heuman DM; Sikaroodi M; Iyer RK; Gillevet PM; Bajaj JS
J Hepatol; 2021 Jan; 74(1):80-88. PubMed ID: 32679299
[TBL] [Abstract][Full Text] [Related]
5. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity.
Kaji K; Takaya H; Saikawa S; Furukawa M; Sato S; Kawaratani H; Kitade M; Moriya K; Namisaki T; Akahane T; Mitoro A; Yoshiji H
World J Gastroenterol; 2017 Dec; 23(47):8355-8366. PubMed ID: 29307995
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Effect of Rifaximin with and without Lactulose on the Active Bacterial Assemblages in the Proximal Small Bowel and Faeces in Patients with Minimal Hepatic Encephalopathy.
Schulz C; Schütte K; Vilchez-Vargas R; Vasapolli R; Malfertheiner P
Dig Dis; 2019; 37(2):161-169. PubMed ID: 30428474
[TBL] [Abstract][Full Text] [Related]
7. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy.
Bajaj JS; Heuman DM; Sanyal AJ; Hylemon PB; Sterling RK; Stravitz RT; Fuchs M; Ridlon JM; Daita K; Monteith P; Noble NA; White MB; Fisher A; Sikaroodi M; Rangwala H; Gillevet PM
PLoS One; 2013; 8(4):e60042. PubMed ID: 23565181
[TBL] [Abstract][Full Text] [Related]
8. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P
Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775
[TBL] [Abstract][Full Text] [Related]
9. Impact of Antibiotic Resistance Genes in Gut Microbiome of Patients With Cirrhosis.
Shamsaddini A; Gillevet PM; Acharya C; Fagan A; Gavis E; Sikaroodi M; McGeorge S; Khoruts A; Albhaisi S; Fuchs M; Sterling RK; Bajaj JS
Gastroenterology; 2021 Aug; 161(2):508-521.e7. PubMed ID: 33857456
[TBL] [Abstract][Full Text] [Related]
10. Low-dose rifaximin prevents complications and improves survival in patients with decompensated liver cirrhosis.
Zeng X; Sheng X; Wang PQ; Xin HG; Guo YB; Lin Y; Zhong JW; He CZ; Yin J; Liu TT; Ma WJ; Xiao X; Shi PM; Yuan ZL; Yang L; Ma X; Xu JM; Shen XZ; Yang CQ; Zhu X; Lv NH; Xie WF
Hepatol Int; 2021 Feb; 15(1):155-165. PubMed ID: 33385299
[TBL] [Abstract][Full Text] [Related]
11. Rifaximin improves survival in cirrhotic patients with refractory ascites: A real-world study.
Lv XY; Ding HG; Zheng JF; Fan CL; Li L
World J Gastroenterol; 2020 Jan; 26(2):199-218. PubMed ID: 31988585
[TBL] [Abstract][Full Text] [Related]
12. The Link between Gut Microbiota and Hepatic Encephalopathy.
Won SM; Oh KK; Gupta H; Ganesan R; Sharma SP; Jeong JJ; Yoon SJ; Jeong MK; Min BH; Hyun JY; Park HJ; Eom JA; Lee SB; Cha MG; Kwon GH; Choi MR; Kim DJ; Suk KT
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012266
[TBL] [Abstract][Full Text] [Related]
13. Rifaximin microbial resistance and its efficacy and safety as a secondary prophylaxis of hepatic encephalopathy in patients with hepatitis C virus-related cirrhosis.
Abdel Moneim M; Abdelaziz DH; Ibrahim Nagy Y; Abdel Baki A; Attia AS; Sabry N
Int J Clin Pract; 2021 Nov; 75(11):e14807. PubMed ID: 34487412
[TBL] [Abstract][Full Text] [Related]
14. Prevention and treatment of hepatic encephalopathy: focusing on gut microbiota.
Garcovich M; Zocco MA; Roccarina D; Ponziani FR; Gasbarrini A
World J Gastroenterol; 2012 Dec; 18(46):6693-700. PubMed ID: 23239905
[TBL] [Abstract][Full Text] [Related]
15. The role of microbiota in hepatic encephalopathy.
Bajaj JS
Gut Microbes; 2014; 5(3):397-403. PubMed ID: 24690956
[TBL] [Abstract][Full Text] [Related]
16. Distinct responsiveness to rifaximin in patients with hepatic encephalopathy depends on functional gut microbial species.
Yukawa-Muto Y; Kamiya T; Fujii H; Mori H; Toyoda A; Sato I; Konishi Y; Hirayama A; Hara E; Fukuda S; Kawada N; Ohtani N
Hepatol Commun; 2022 Aug; 6(8):2090-2104. PubMed ID: 35429147
[TBL] [Abstract][Full Text] [Related]
17. The Use of Rifaximin in Patients With Cirrhosis.
Caraceni P; Vargas V; Solà E; Alessandria C; de Wit K; Trebicka J; Angeli P; Mookerjee RP; Durand F; Pose E; Krag A; Bajaj JS; Beuers U; Ginès P;
Hepatology; 2021 Sep; 74(3):1660-1673. PubMed ID: 33421158
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the effects of probiotics, rifaximin, and lactulose in the treatment of minimal hepatic encephalopathy and gut microbiota.
Wang MW; Ma WJ; Wang Y; Ma XH; Xue YF; Guan J; Chen X
Front Microbiol; 2023; 14():1091167. PubMed ID: 37032856
[TBL] [Abstract][Full Text] [Related]
19. Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications.
Ponziani FR; Gerardi V; Pecere S; D'Aversa F; Lopetuso L; Zocco MA; Pompili M; Gasbarrini A
World J Gastroenterol; 2015 Nov; 21(43):12322-33. PubMed ID: 26604640
[TBL] [Abstract][Full Text] [Related]
20. Breakthrough Clostridium difficile Infection in Cirrhotic Patients Receiving Rifaximin.
Reigadas E; Alcalá L; Gómez J; Marín M; Martin A; Onori R; Muñoz P; Bouza E
Clin Infect Dis; 2018 Mar; 66(7):1086-1091. PubMed ID: 29069372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
